Balixafortide

CXCR4 responds to a chemokine called CXCL12, also known as SDF-1α. This signaling axis regulates how immune cells travel and settle, and it shapes the environment around tumors¹. CXCL12 also helps hold blood-forming stem cells in the bone marrow. Balixafortide occupies CXCR4 and blocks that signal; it came out of Polyphor's macrocycle platform⁶ and is described as a protein epitope mimetic, a peptide built to imitate a small part of a protein surface³.

In healthy volunteers, blocking this signal released stem cells and white blood cells from the marrow into the bloodstream, with white-cell counts largely back to normal within 24 hours². The cancer rationale is that disrupting CXCR4 signaling may leave tumor cells and their surroundings more exposed to chemotherapy, an effect reported in animal models^1,3.

Nearly all human data come from company-sponsored trials. In a phase 1 study in healthy men, a single infusion mobilized blood stem cells to levels the authors predicted would be enough for a standard apheresis collection, and it was well tolerated².

In a phase 1 trial of 56 women with heavily pretreated HER2-negative metastatic breast cancer, balixafortide plus the chemotherapy eribulin produced partial tumor responses in 30% of evaluable patients, but the study had no comparison group¹. A randomized phase 3 trial in 432 patients then compared the combination with eribulin alone and was halted for failing its primary endpoint: median progression-free survival was about 3.5 months with the combination and 4.0 months with eribulin alone, and overall survival did not differ⁴.

In mice with prostate cancer growing in bone, adding it to docetaxel reduced tumor burden more than docetaxel alone³. A small investigator-led phase 1 trial pairing it with an immunotherapy in pancreatic cancer is listed as not yet recruiting⁵.

Balixafortide is not approved by the FDA or any other regulator. Its lead breast cancer program ended after the phase 3 trial missed its primary endpoint⁴.

In the breast cancer phase 1 trial, where it was given with chemotherapy, the most common events were fatigue, low neutrophil counts, infusion-related reactions, hair loss, constipation and nausea; serious adverse events occurred in 38% of patients, two of the 56 died while on study treatment (septic shock and pneumonia), and a treatment-related death in the first dose group led to a protocol amendment¹. In healthy volunteers it caused a temporary rise in white blood cells². There are no long-term human data.

1. Pernas et al., Lancet Oncol 2018PubMed
2. Karpova et al., J Transl Med 2017PubMed
3. Robinson et al., Prostate 2023PubMed
4. ClinicalTrials.gov: NCT03786094 (phase 3, results)ClinicalTrials.gov
5. ClinicalTrials.gov: NCT06981806ClinicalTrials.gov
6. Batur et al., Chimia 2021PubMed